植入式心律转复除颤器与射血分数改善患者生存的关联:SCD-HeFT二次分析
该研究基于SCD-HeFT试验的二次分析,纳入1902例基线EF≤35%并重复评估EF的患者,比较安慰剂组与ICD组。结果显示,无论随访EF是否改善至>35%,ICD均与全因死亡率降低相关,且治疗与EF无交互作用。
要点
- SCD-HeFT二次分析显示,EF改善至>35%者接受ICD治疗仍有死亡风险相对下降。
- EF持续≤35%者ICD降低全因死亡率(校正HR 0.64,95%CI 0.48-0.85)。
- EF改善至>35%者ICD效应相似但未达统计学显著(校正HR 0.62,95%CI 0.29-1.30)。
核心结论
- 在SCD-HeFT重复评估EF的参与者中,EF改善至>35%者接受ICD治疗的全因死亡相对下降与EF持续≤35%者相似。
- 需前瞻性随机临床试验验证ICD在EF>35%患者中的疗效。
研究设计与样本
- SCD-HeFT试验的回顾性二次分析,1997-2001年随机分配2521例患者至安慰剂、胺碘酮或ICD。
- 1902例(75.4%)在随机后平均13.5(标准差6)个月重复评估EF,其中1273例纳入本次分析(安慰剂649例,ICD624例)。
主要发现
- 重复EF>35%者:ICD组186例(29.8%),安慰剂组185例(28.5%)。
- 中位随访30个月,全因死亡率:EF持续≤35%者ICD组7.7 vs 安慰剂组10.7/100人年;EF改善至>35%者ICD组2.6 vs 安慰剂组4.5/100人年。
- 校正后ICD对死亡的风险比:EF≤35%者为0.64(95%CI 0.48-0.85),EF>35%者为0.62(95%CI 0.29-1.30)。
- 治疗分配与重复EF之间无交互作用(预测死亡率)。
临床怎么用
- 对于基线EF≤35%且随访EF改善至>35%的患者,ICD治疗可能仍带来死亡风险相对下降,但证据尚待前瞻性试验确认。
局限性
- 为回顾性二次分析,仅纳入有重复EF评估的亚组,可能存在选择偏倚。
- EF改善至>35%亚组的ICD效应置信区间宽且未达统计学显著。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Improvement in left ventricular ejection fraction (EF) to >35% occurs in many patients with reduced EF at baseline. To our knowledge, whether implantable cardioverter defibrillator (ICD) therapy improves survival for these patients is unknown. OBJECTIVE: To examine the efficacy of ICD therapy in reducing risk of all-cause mortality and sudden cardiac death among patients with an EF ≤35% at baseline, with or without an improvement in EF to >35% during follow-up. DESIGN, SETTING, AND PARTICIPANTS: This retrospective analysis examined data collected in the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT), which randomly assigned 2521 patients to placebo, amiodarone, or ICD between 1997 and 2001. A subset of 1902 participants (75.4%) of the SCD-HeFT had a repeated assessment of EF a mean (SD) of 13.5 (6) months after randomization. We stratified these patients by EF ≤35% and >35% based on the first repeated EF measurement after randomization and compared all-cause mortality in 649 patients randomized to placebo vs 624 patients randomized to ICD. Follow-up started with the repeated EF assessment. Analysis was performed between January 2016 and July 2016. EXPOSURES: Implantable cardioverter-defibrillator therapy. MAIN OUTCOMES AND MEASURES: All-cause mortality and sudden cardiac death. RESULTS: Of the included 1273 patients, the mean (SD) age was 59 (12) years, and 977 (76.7%) were male and 1009 (79.3%) were white. Repeated EF was >35% in 186 participants (29.8%) randomized to ICD and 185 participants (28.5%) randomized to placebo. During a median follow-up of 30 months, the all-cause mortality rate was lower in the ICD vs placebo group, both in patients whose EF remained ≤35% (7.7 vs 10.7 per 100 person-year follow-up) and in those whose EF improved to >35% (2.6 vs 4.5 per 100 person-year follow-up). Compared with placebo, the adjusted hazard ratio for the effect of ICD on mortality was 0.64 (95% CI, 0.48-0.85) in patients with a repeated EF of ≤35% and 0.62 (95% CI, 0.29-1.30) in those with a repeated EF >35%. There was no interaction between treatment assignment and repeated EF for predicting mortality. CONCLUSIONS AND RELEVANCE: Among participants in the SCD-HeFT who had a repeated EF assessment during the course of follow-up, those who had an improvement in EF to >35% accrued a similar relative reduction in mortality with ICD therapy as those whose EF remained ≤35%. Prospective randomized clinical trials are needed to test ICD efficacy in patients with an EF >35%. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01114269.
引用
- Adabag S, Patton KK, Buxton AE, et al. Association of Implantable Cardioverter Defibrillators With Survival in Patients With and Without Improved Ejection Fraction: Secondary Analysis of the Sudden Cardiac Death in Heart Failure Trial. JAMA Cardiol. 2017. PMID: 28724134. doi:10.1001/jamacardio.2017.1413
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。